> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novogen Submits IND for Cantrixil in Ovarian Cancer
- URL: https://www.fdaweb.com/novogen-submits-ind-for-cantrixil-in-ovarian-cancer/
- Published: 2016-08-11T12:00:00.000Z
- Updated: 2026-09-14T21:23:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5136486

Australia-based Novogen has submitted an IND for TRX-E-002-1 (cantrixil) for treating ovarian cancer. The submission includes data on preclinical pharmacology and toxicity, manufacturing, quality control, and clinical development plans. Cantrixil is described as a first-in-class development candidate which is being studied as a therapy for ovarian cancer, administered directly into the abdominal cavity via the intra-peritoneal route. “Preclinical data has shown broad-based evidence of anti-tumor activity in animal models of ovarian cancer, and a toxicology program conducted under Good Laboratory Practices has demonstrated a toxicity profile that appears appropriate for use in humans at therapeutic doses,” according to the company.